GUS Inhibitors
1 drugsAbout GUS
GUS (Glucuronidase) enzymes catalyze the breakdown of glucuronic acid, a uronic acid found in plant gums and animal connective tissues.
MEPSEVII's approval highlights GUS's potential as a therapeutic target, though no genetic evidence currently links GUS to specific diseases.
GUS is targeted by one FDA-approved biologic drug, MEPSEVII, developed by ULTRAGENYX PHARM INC for a single indication.
Top GUS Drugs
ULTRAGENYX PHARM INC is the only company with an approved drug targeting GUS.
Low competition suggests a potential market entry opportunity, but also highlights the risk.
GUS Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GUS, using enzyme modality.
The lack of modality diversity indicates a whitespace opportunity for small molecules or other approaches.
GUS Drug Approval Timeline (2017 - 2017)
MEPSEVII was both the first and most recent drug approved in 2017.
The lack of recent approvals suggests market saturation or challenges in developing new GUS-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline